← Oncology Approval Tracker

FDA DECISION ·

Sarclisa Escena + carfilzomib + dexamethasone

subcutaneous isatuximab-irfc with carfilzomib and dexamethasone · Sanofi

FDA approvalNew formulationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after one to three prior lines of therapy.

LAMPGEN ANALYSIS

Why it matters

This makes subcutaneous isatuximab available in a second relapsed-disease combination. IZALCO supplied regimen-specific response data from a phase 2 study.

What research teams should watch

Match prior-line counts and the specific combination to the order set. Formulation training still needs to account for the accompanying drugs and their safety procedures.

PRIMARY RECORDS

Sources